Woman 'finds out her ovarian cyst was a teratoma with hair, teeth, eyeball that killed her ovary': Doctor explains
Teratomas are tumours
She wrote about her video: 'Me waking up after surgery finding out my 'ovarian cyst' was actually a teratoma with hair, teeth and an eyeball? And that it grew so big, it twisted and killed my ovary.'
In his caption, Dr Sood wrote, 'Some ovarian 'cysts' turn out to be teratomas: tumours that can contain fat, hair, or even teeth. Most are benign, but larger ones can cause serious complications like ovarian torsion, which may affect fertility. Did you know not all cysts are just cysts?'
'They can twist the ovary'
In the video he posted, Dr Sood explained, 'Believe it or not, this can actually happen. Teratomas are tumours that contain hair, skin, and even teeth. They're most often found in the ovaries. They sometimes look like simple cysts on imaging. But unlike fluid-filled cysts, teratomas often contain fat or calcifications and form from germ cells, not normal ovarian tissue. Most are benign.'
He added, 'But if they grow larger than 5 to 10 cm, they can twist the ovary, a complication called ovarian torsion. This cuts off blood flow and, without urgent surgery, can permanently damage or destroy the ovary, putting fertility at risk. Distinguishing between a cyst and a teratoma early is critical. Diagnosis often depends on a combination of imaging, clinical exam, and sometimes surgery to confirm.'
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
28 minutes ago
- Hindustan Times
Justin Timberlake, Avril Lavigne, Justin Bieber and more: Celebs who have opened up about their Lyme disease battles
Justin Timberlake shocked his fans with the revelation that he has been battling Lyme disease, describing it as a 'relentlessly debilitating' condition in a candid Instagram post. The announcement comes after the singer faced intense backlash over recent world tour performances, with some fans criticizing him for appearing 'lazy' and 'tired' on stage, as reported by The Sun. Justin Timberlake disclosed his struggle with Lyme disease after facing backlash for his tour performances. (Carsten Koall/dpa via AP)(AP) Also Read: Justin Timberlake Lyme disease: Singer opens up on health struggles; fans ask, 'Is there a cure?' What is Lyme disease? According to the EDS Clinic, Lyme disease is a bacterial infection transmitted through the bite of an infected tick. It often begins with flu-like symptoms and may include fatigue, joint pain, and a distinctive 'bullseye' rash around the bite site. If detected at an early stage, it can be cured with the help of antibiotics. Delaying treatment for Lyme disease can lead to debilitating symptoms, including nerve damage and heart rhythm disturbances. For some people, the symptoms of Lyme disease persist for months after they are diagnosed with infection. This condition is known as long Lyme Chronic lyme disease. Symptoms of this include severe fatigue, joint and muscle pain, and cognitive issues. Also Read: Hulk Hogan cause of death: What is acute myocardial infarction and leukemia's role? Other celebs diagnosed with Lyme disease Many celebrities have been diagnosed with it and have shared their journey in public to raise awareness about the often misunderstood disease. Following is the list of celebrities who have been vocal about their Lyme disease. Avril Lavigne Justin Bieber Yolanda Hadid Bella Hadid Ben Stiller Shania Twain Alec Baldwin Amy Schumer Kelly Osbourne Ramona Singer Fletcher Debbie Gibson Ryan Sutter Kelley Flanagan Riley Keough Ally Hilfiger Miranda Hart Kris Kristofferson
Hindustan Times
29 minutes ago
- Hindustan Times
Justin Timberlake Lyme disease: Singer opens up on health struggles; fans ask, ‘Is there a cure?'
Justin Timberlake revealed that he has been diagnosed with Lyme disease. The singer, in a lengthy social media post, reflected on his health struggles and addressed concerns about his Forget Tomorrow tour, which wrapped up this week. Justin Timberlake performs at the 2025 BottleRock Napa Valley(AP) 'I've been battling some health issues, and was diagnosed with Lyme disease -— which I don't say so you feel bad for me –– but to shed some light on what I've been up against behind the scenes,' the 44-year-old wrote on Instagram. The pop star attached photos from his tour. "As I'm reflecting on the tour and festival tour — I want to tell you a little bit about what's going on with me.' 'If you've experienced this disease or know someone who has — then you're aware: living with this can be relentlessly debilitating, both mentally and physically. When I first got the diagnosis I was shocked for sure. But, at least I could understand why I would be onstage and in a massive amount of nerve pain or, just feeling crazy fatigue or sickness. I was faced with a personal decision. Stop touring? Or, keep going and figure it out. I decided the joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going," he further added. Timberlake's announcement has worried fans. One of them asked on X: 'Is there a cure for Lyme disease?' What is Lyme disease? According to the Mayo Clinic, Lyme disease is caused by borrelia bacteria, which is carried by some ticks. Symptoms include rashes, body pain and stiffness, muscle weakness and immune-system issues. Can Lyme disease be cured? As per Centers for Disease Control and Prevention (CDC), 'most cases of Lyme disease can be treated with 10-14 days of antibiotics'. 'People treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely.'
Time of India
33 minutes ago
- Time of India
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Explore courses from Top Institutes in Please select course: Select a Course Category healthcare Project Management Finance Technology Operations Management Artificial Intelligence Data Science Management PGDM Data Science Product Management Degree Others Healthcare Public Policy Design Thinking Cybersecurity Digital Marketing others CXO Leadership MCA MBA Data Analytics Skills you'll gain: Duration: 11 Months IIM Lucknow CERT-IIML Healthcare Management India Starts on undefined Get Details Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 15 Most Beautiful Women in the World Undo "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." Live Events AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
